AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01522989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
Study NCT01522989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
Study NCT01522989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus.
Study NCT00662610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 375 mg -750 mg -1125 mg bid
Description: naproxcinod 375 mg -750 mg -1125 mg bid
Study NCT00662610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen 250 mg - 500mg -750 mg bid
Description: naproxen 250 mg - 500mg -750 mg bid
Study NCT03096054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3143921 hydrate
Description: LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
Study NCT01685931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
Study NCT02105792 — intervention group
Intervention type: DRUG
Intervention: second- or third-line glucose-lowering diabetes treatment
Description: Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
Study NCT00785395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Description: Up-down dosing determination
Study NCT04204954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea Tree Oil Shampoo
Description: Twice a day eyelid margin cleansing for three days.
Study NCT04204954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin Ophthalmic Ointment 0.3%
Description: Applied topically in the eyelid margin every four hours for three days.
Study NCT04204954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin Ophthalmic Ointment 0.3%
Description: Applied topically in the eyelid margin every four hours for three days.
Study NCT04204954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Ophthalmic Ointment 0.3%
Description: Applied topically in the eyelid margin every four hours for three days.
Study NCT04204954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baby shampoo
Description: Twice a day eyelid margin cleansing for three days.
Study NCT04204954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blephaclean
Description: Twice a day eyelid margin cleansing for three days.
Study NCT03940664 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry on Formalin fixed and paraffin embedded blocks
Study NCT00588848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoadjusting CPAP (VPAP Auto)
Description: An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
Study NCT00588848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
Study NCT02187484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 277
Study NCT06278584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iLUX Treatment System
Description: Local heat using an electrical warming mask for 5 minutes.
Study NCT01562964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
Study NCT01562964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy
Description: Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
Study NCT04190485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.
Study NCT04190485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMNL-143 Probiotic Toothpastes
Description: Subjects will be randomized to one of two groups, using GMNL-143 probiotic toothpastes toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
Study NCT04190485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMNL-464 Probiotic Toothpastes
Description: Subjects will be randomized to one of two groups, using GMNL-464 probiotic toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
Study NCT01606098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of the primary tumour
Description: Surgical resection of the colon tumour
Study NCT01606098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic treatment
Description: First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)
Study NCT01606098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic treatment
Description: First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)
Study NCT02469025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual caudal traction mobilization in resting position
Study NCT02469025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual caudal traction mobilization in end range position
Study NCT02469025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selftreatment
Description: Each subject is advice to do some exercises at home
Study NCT05919732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, Dexmedetomidine, Caffeine, Tylenol
Description: bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg). Dexmedetomidine 0.5mcg/kg, Caffeine 15mg/kg, rectal Tylenol 30mg/kg
Study NCT05919732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol, rocuronium, caffeine, Tylenol, bupivacaine
Description: propofol 3mg/kg and rocuronium 0.6mg/kg. Caffeine 15mg/kg and rectal Tylenol 30mg/kg.~single shot caudal with bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg)
Study NCT00630500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Tablets, 5 or 10 mg, twice daily
Study NCT00630500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets corresponding to 5 or 10 mg, twice daily, 6 months
Study NCT03250793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer
Description: While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
Study NCT02941692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT02941692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Oxytocin
Study NCT02113449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide
Description: Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
Study NCT02662205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy Group
Description: Traditional process group
Study NCT02662205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga class
Description: Yin yoga class
Study NCT02662205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy Group
Description: Yoga psychotherapy group integrating yoga and process dialogue
Study NCT02346357 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obturator Nerve Block
Description: Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
Study NCT02346357 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Obturator Nerve Block
Description: Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
Study NCT02346357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT00119002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 1mg/kg dexamethasone
Study NCT00119002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1mg/kg placebo
Study NCT00068549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT00068549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00068549 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo whole pelvis radiotherapy
Study NCT00068549 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy
Study NCT01657149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphatic massage and individual physiotherapy
Description: lymphatic massage and individual physiotherapy
Study NCT01657149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: individual physiotherapy only
Description: individual physiotherapy only
Study NCT03971227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuity 200 (Fluoroxyfocon A) contact lens
Description: Daily wear rigid gas permeable contact lens
Study NCT02703870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS
Description: sham transcranial direct current stimulation, 10 sessions, for 20 minutes
Study NCT02703870 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: sham transcranial direct current stimulation, 10 sessions, for 20 minutes
Study NCT02703870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VRT
Description: Vision restoration training, 10 sessions, 20 minutes
Study NCT02703870 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: VRT
Description: Vision restoration training, 10 sessions, 20 minutes
Study NCT00774150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 16 sessions of CBT
Study NCT00774150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Client Centered Therapy
Description: 16 sessions of CCT
Study NCT02346357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Study NCT03698383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilars(Herzuma), Gedatolisib
Description: * Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~* Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg
Study NCT04827849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured education and follow-up
Description: The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period.
Study NCT05423938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diabetic
Description: It is a hypercaloric and hyperproteic dietary supplement formulated to contribute to control the glycemia with: a specific mix of carbohydrate with a low GI, fiber, EVOO and EPA\&DHA
Study NCT05423938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: It is a hypercaloric and hyperproteic dietary supplement formulated without the ingredients to contribute in the glycemia control
Study NCT00445848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00445848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT00659217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: Autologous MSC transplantation
Study NCT01442506 — intervention group
Intervention type: OTHER
Intervention: biopsies
Description: taking biopsies
Study NCT01442506 — intervention group
Intervention type: OTHER
Intervention: biopsy
Description: biopsy
Study NCT06761573 — intervention group
Intervention type: DEVICE
Intervention: Bilateral Bispetral Index Monitor will be applied on forehead of our patients, before surgery begins
Description: In patients undergoing surgery and general anesthesia, the investigators want to examine -using bilateral BIS monitor- synthetic electroencephalographic differences between the two cerebral hemispheres (ASYM) to evaluate any correlation with the development of POD and POCD in the post-operative period.
Study NCT06761430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearPlasma
Description: ClearPlasmais an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasmaTM is a non-pyrogenic, sterile, single-use medical device.
Study NCT01817673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 20 g/d for 5 d followed by 5 g/d throughout the trial
Study NCT01817673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02736266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
Study NCT02187523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Study NCT02187523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02187523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/HCTZ FDC
Study NCT02098369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written education material (basic)
Description: Education material on COPD distributed to all participants.
Study NCT01385800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: Intradermal injection 1 x 8 administrations 2 weeks apart
Study NCT02098369 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Written education material (basic)
Description: Education material on COPD distributed to all participants.
Study NCT02098369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional education material
Description: Additional education material sent to participants in the proactive and reactive arms.
Study NCT02098369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PELICAN-Proactive
Description: In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
Study NCT02098369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PELICAN-Reactive
Description: Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
Study NCT03975127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS text
Description: A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
Study NCT01991223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dex infusion
Description: Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
Study NCT01991223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NS infusion
Description: Normal saline will be infused during surgery
Study NCT01633515 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intralesional cryotherapy
Description: The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received).